½ÃÀ庸°í¼­
»óǰÄÚµå
1611181

Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ¿öÅ©Ç÷ο캰, ¸ðµåº°, ¸®µå ±æÀ̺°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Next-generation Sequencing Data Analysis Market Size, Share & Trends Analysis Report By Product (Services, NGS Commercial Software), By Workflow (Primary, Secondary), By Mode, By Read Length, By End Use, By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ¼¼°è ½ÃÀå ±Ô¸ð´Â 2025-2030³â µ¿¾È CAGR 23.10%·Î È®´ëµÇ¾î 2030³â¿¡´Â 34¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀÇ ¹è°æ¿¡´Â ÀÓ»ó Áø´Ü¿¡¼­ NGS µµÀÔ ºñ¿ëÀÌ Å©°Ô °¨¼ÒÇ߱⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, À¯Àüü ¹× ´Ü¹éÁúüÇÐ µ¥ÀÌÅÍ¿¡ ´ëÇÑ Á¢±ÙÀÌ °¡´ÉÇØÁü¿¡ µû¶ó Å« ¼ºÀå ±âȸ°¡ âÃâµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ¿¡ÇÇÁ¨ÅØ ±×·ì(EpiGentek Group Inc.)ÀÇ Targeted Methyl-Seq Ç÷§Æû, ¾ÖÁú·±Æ®(Agilent)ÀÇ HaloPlex ĸó ½Ã½ºÅÛ µî ´Ù¾çÇÑ ÅøÀÌ Ãâ½ÃµÊ¿¡ µû¶ó NGS µµÀÔ·üÀÌ ´õ¿í ³ô¾ÆÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÇ Targeted Methyl-Seq Ç÷§Æû, AgilentÀÇ HaloPlex ĸó ½Ã½ºÅÛ µîÀÇ µµ±¸°¡ °³º° À¯ÀüüÀÇ DNA ¸Þƿȭ ÇÁ·ÎÆÄÀÏÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖÀ¸¸ç, COVID-19 ÆÒµ¥¹ÍÀº NGSÀÇ È°¿ëÀ» ÃËÁøÇÏ¿© Å« ¼ö¿ä¸¦ âÃâÇß½À´Ï´Ù.

NGS µµ±¸´Â °úÇÐÀÚµéÀÌ ºÐ¼®ÇÏ°í º´¿ø¼ºÀ» ¿¬±¸ÇÒ ¼ö ÀÖ´Â ´ë·®ÀÇ µ¥ÀÌÅ͸¦ »ý¼ºÇÒ ¼ö ÀÖ½À´Ï´Ù. »ê-ÇÐ-°ü ¿¬±¸ÀÚµéÀº µ¥ÀÌÅÍ ºÐ¼® ±â¼úÀ» »ç¿ëÇÏ¿© SARS-CoV2ÀÇ Æ¯Â¡, °èÅë, °úÁ¤À» ±Ô¸íÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖÀ¸¸ç, NGS ±â¼úÀº ±âÁ¸ ±â¼ú·Î´Â ¾ÆÁ÷ ¿¬±¸µÇÁö ¾ÊÀº »ý¹°ÇÐÀû Á¤º¸¸¦ ±Ô¸íÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, NGS´Â ´Ù¾çÇÑ »ý¹°ÇÐÀû °úÁ¤°ú ÈļºÀ¯ÀüüÇÐ °ü·Ã À¯Àüü ÆÐÅÏ ¿¬±¸¿¡ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ½ºÅ丮Áö °ü¸® ¹× µ¥ÀÌÅÍ ºÐ¼®¿¡ ´ëÇÑ Á¢±Ù°ú °ü·ÃµÈ ¹®Á¦´Â ¾öû³­ ¿¬±¸ °³¹ß Àü¸ÁÀ» °¡Á®´Ù ÁÙ °ÍÀ¸·Î ¿¹»óµÇ¸ç, »ê¾÷ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. °í¼º´É ½ÃÄö¼­¸¦ »ç¿ëÇÏ´Â ¿¬±¸ÀÚµéÀº ½ÃÄö½Ì Á¤º¸¸¦ º¸°üÇϰí ó¸®Çϱâ À§ÇØ ½ÇÇè½Ç Á¤º¸ °ü¸® ½Ã½ºÅÛ(LIMS)°ú °°Àº ¼ÒÇÁÆ®¿þ¾î ½Ã½ºÅÛÀ» ÇÊ¿ä·Î ÇÕ´Ï´Ù.

¶ÇÇÑ, Galaxy³ª Chipster¿Í °°Àº ¿öÅ©ÇÃ·Î¿ì °ü¸® ½Ã½ºÅÛ ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀº µ¥ÀÌÅÍ ÀúÀå ¹× °ü¸®ÀÇ ±â¼úÀû Áøº¸¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ »ý¼ººÎÅÍ ¿¹ºñ ºÐ¼®, °í±Þ ºÐ¼®¿¡ À̸£´Â µ¥ÀÌÅÍ ºÐ¼® ÇÁ·Î¼¼½ºÀÇ È帧À» ¸ð´ÏÅ͸µÇÏ´Â ±â¼úÀûÀ¸·Î Áøº¸µÈ ÀÎÇÁ¶ó¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, NGS µ¥ÀÌÅÍ ºÐ¼® µµ±¸´Â È¿°úÀûÀÎ °á°ú¿Í ³ôÀº ½Ç¿ë¼ºÀ» À§ÇØ Áö¼ÓÀûÀ¸·Î ¾÷±×·¹À̵åµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹ÙÀÌ¿À³ª³ëÁö³ë¹Í½º´Â 2021³â 12¿ù À¯Àüü ºÐ¼®À» À§ÇÑ ¹ÙÀÌ¿Àµð½ºÄ¿¹ö¸®ÀÇ NxClinical Software Version 6.1À» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ¹öÀüÀº ¾Ï ¹× À¯Àü¼º Áúȯ ¿µ¿ª¿¡¼­ NGS µ¥ÀÌÅÍÀÇ ½Ã°¢È­ ¹× ÇØ¼®À» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °³¹ßÀº ¿¹Ãø ±â°£ µ¿¾È ¾÷°è¸¦ ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • 2024³â ¼­ºñ½º ¹× Á¦Ç° ºÎ¹®ÀÌ »ê¾÷À» Áö¹èÇÒ °Í NGS´Â ¼Óµµ¿Í °¡°Ý Ãø¸é¿¡¼­ ¸î °¡Áö ÀåÁ¡ÀÌ ÀÖÁö¸¸, ¼÷·ÃµÈ Àü¹®°¡¿Í ÃæºÐÇÑ ÄÄÇ»ÆÃ ÀÎÇÁ¶ó°¡ ¾ø±â ¶§¹®¿¡ ¸¹Àº ¿¬±¸ ±â°üÀÌ Ã¤ÅÃÇÏÁö ¸øÇϰí ÀÖ½À´Ï´Ù.
  • 3Â÷ ¿öÅ©ÇÃ·Î¿ì ºÎ¹®Àº °á°ú ÇØ¼® ¹× °ü·Ã NGSÀÇ º¹ÀâÇϰí Áß¿äÇÑ ´Ü°è¸¦ Â÷ÁöÇϱ⠶§¹®¿¡ 2024³â ÁÖ¿ä ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • 2024³â ½ÃÀåÀº »ç³» µ¥ÀÌÅÍ ºÐ¼® ¸ðµå ºÎ¹®ÀÌ Áö¹èÀûÀ̾úÀ¸¸ç, ¾ÕÀ¸·Îµµ °è¼Ó Áö¹èÀûÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ½Ã°£°ú ºñ¿ëÀÇ ÀÌÁ¡À¸·Î ÀÎÇØ 2025-2030³â¿¡´Â ¾Æ¿ô¼Ò½Ì ¸ðµå ºÎ¹®ÀÌ °¡Àå ºü¸¥ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
  • ´Üµ¶ ¸®µå ½ÃÄö½Ì ºÎ¹®Àº ³ôÀº äÅ÷ü, ºñ¿ë È¿À²¼º, DNA ´ÜÆí ó¸® ´É·Â, ¿©·¯ µµ±¸ ¹× ¾Ë°í¸®ÁòÀÇ °¡¿ë¼ºÀ¸·Î ÀÎÇØ 2024³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • Çмú ¿¬±¸ ÃÖÁ¾ ¿ëµµ ºÎ¹®ÀÌ 2024³â ½ÃÀåÀ» Àå¾ÇÇßÀ¸¸ç, NGS ±â¼ú ºñ¿ëÀÇ °¨¼Ò´Â µ¥ÀÌÅÍ ÇØ¼®ÀÌ ÇÊ¿äÇÑ ¿¬±¸¸¦ À§ÇØ ¿©·¯ ¿¬±¸ ¼¾ÅÍ¿Í Çмú ±â°ü¿¡¼­ NGS ¼ÒÇÁÆ®¿þ¾î Ç÷§ÆûÀÇ »ç¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
  • ºÏ¹Ì´Â Àß ¹ß´ÞµÈ Á¤º¸ ±â¼ú ȸ»çÀÇ Á¸Àç, À¯¸®ÇÑ »óȯ ³×Æ®¿öÅ©, »ý¸í°øÇÐ ºÎ¹®ÀÇ ³ôÀº Á¤ºÎ ÀÚ±Ý ¹× ³ôÀº °ø°ø ¹× ¹Î°£ ÁöÃâ·Î ÀÎÇØ 2024³â¿¡ °¡Àå ³ôÀº ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • °ü·Ã/º¸Á¶ ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • »ê¾÷ ºÐ¼® Åø
    • Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
    • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå Á¦Ç° ºñÁî´Ï½º ºÐ¼®

  • Á¦Ç° ºÎ¹® ´ë½Ãº¸µå
  • Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå Á¦Ç° º¯µ¿ ºÐ¼®
  • Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Á¦Ç°º°, 2018-2030³â
  • ¼­ºñ½º
    • ¼­ºñ½º ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
  • NGS »ó¾÷¿ë ¼ÒÇÁÆ®¿þ¾î
    • NGS »ó¾÷¿ë ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • Ç÷§Æû OS/UI
    • ºÐ¼® ¼ÒÇÁÆ®¿þ¾î

Á¦5Àå ¿öÅ©ÇÃ·Î¿ì ºñÁî´Ï½º ºÐ¼®

  • ¿öÅ©ÇÃ·Î¿ì ºÎ¹® ´ë½Ãº¸µå
  • Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå ¿öÅ©ÇÃ·Î¿ì º¯µ¿ ºÐ¼®
  • Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¿öÅ©Ç÷ο캰, 2018-2030³â
  • 1Â÷
    • 1Â÷ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
  • 2Â÷
    • 2Â÷ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ¸®µå ¸ÅÇÎ
    • º¯ÀÌü ¾ó¶óÀÎ¸ÕÆ®¿Í º¯ÀÌü È£Ãâ
  • 3Â÷
    • 3Â÷ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • º¯ÀÌü ¾î³ëÅ×À̼Ç
    • ¿ëµµ °íÀ¯

Á¦6Àå ¸ðµå ºñÁî´Ï½º ºÐ¼®

  • ¸ðµå ºÎ¹® ´ë½Ãº¸µå
  • Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå ¸ðµå º¯µ¿ ºÐ¼®
  • Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¸ðµåº°, 2018-2030³â
  • »ç³» µ¥ÀÌÅÍ ºÐ¼®
    • »ç³» µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
  • ¾Æ¿ô¼Ò½Ì µ¥ÀÌÅÍ ºÐ¼®
    • ¾Æ¿ô¼Ò½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â

Á¦7Àå ¸®µå ±æÀÌ ºñÁî´Ï½º ºÐ¼®

  • ¸®µå ±æÀÌ ºÎ¹® ´ë½Ãº¸µå
  • Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå ¸®µå ±æÀÌ º¯µ¿ ºÐ¼®
  • Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¸®µå ±æÀ̺°, 2018-2030³â
  • ¼îÆ® ¸®µå ½ÃÄö½Ì
    • ¼îÆ® ¸®µå ½ÃÄö½Ì ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
  • ·Õ¸®µå ½ÃÄö½Ì
    • ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
  • º£¸® ·Õ¸®µå ½ÃÄö½Ì
    • º£¸® ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â

Á¦8Àå ÃÖÁ¾ ¿ëµµ ºñÁî´Ï½º ºÐ¼®

  • ÃÖÁ¾ ¿ëµµ ºÎ¹® ´ë½Ãº¸µå
  • Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
  • Çмú ¿¬±¸
    • Çмú ¿¬±¸ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
  • ÀÓ»ó ¿¬±¸
    • ÀÓ»ó ¿¬±¸ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
  • º´¿ø¡¤Å¬¸®´Ð
    • º´¿ø¡¤Å¬¸®´Ð ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
  • Á¦¾à°ú ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
    • Á¦¾à°ú ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
  • ±âŸ
    • ±âŸ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â

Á¦9Àå Á¦Ç°, ¿öÅ©Ç÷οì, ¸ðµå, ¸®µå ±æÀÌ, ÃÖÁ¾ ¿ëµµ¿¡ ÀÇÇÑ Áö¿ª ºñÁî´Ï½º ºÐ¼®

  • Áö¿ª ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, 2024³â°ú 2030³â
  • ºÏ¹Ì
    • ºÏ¹ÌÀÇ Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • À¯·´ÀÇ Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå, 2018-2030³â
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå, 2018-2030³â
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ű¹
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå, 2018-2030³â
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Â÷¼¼´ë ½ÃÄö½Ì µ¥ÀÌÅÍ ºÐ¼® ½ÃÀå, 2018-2030³â
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦10Àå °æÀï ±¸µµ

  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ ½ÃÀå »óȲ ºÐ¼®, 2024³â
  • ±â¾÷ °³¿ä/»óÀå ±â¾÷
    • Thermo Fisher Scientific, Inc.
    • Bio-Rad Laboratories, Inc.
    • Pacific Biosciences of California, Inc.
    • QIAGEN
    • Eurofins Scientific
    • Partek Incorporated
    • F. Hoffmann-La Roche Ltd.
    • Illumina, Inc.
    • Agilent Technologies Inc.
    • DNASTAR, Inc
ksm 25.01.03

Next-generation Sequencing Data Analysis Market Growth & Trends:

The global next-generation sequencing data analysis market size is estimated to reach USD 3.45 billion by 2030, expanding at a CAGR of 23.10% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth can be attributed to a significant decline in the cost of NGS installation in clinical diagnosis. Furthermore, the accessibility of genomic and proteomic data is anticipated to create significant growth opportunities. In addition, a reduction in the cost of sequencing is anticipated to boost the adoption rate of NGS, which would further drive the industry. The availability of tools, such as the Targeted Methyl-Seq platform and Agilent's HaloPlex capture system from EpiGentek Group Inc. has aided in the DNA methylation profiles determination in individual genomes. The COVID-19 pandemic has enhanced NGS usage and has created a huge demand.

The NGS tools can generate a significant amount of data for scientists to analyze and study pathogenesis. Researchers from industry, academia, and government have used data analysis technology to help in understanding the characteristics, phylogenetics, and processes of SARS-CoV2. NGS technologies have helped to unveil biological information that has not been studied yet using conventional technologies. For instance, NGS has helped study genomic patterns associated with various biological processes and epigenomics. However, issues related to accessing storage management, and analysis of data are anticipated to offer huge R&D prospects, thus, driving the industry growth. Researchers that use high-throughput sequencers demand software systems, such as Laboratory Information Management Systems (LIMS) to archive and handle sequencing information.

Furthermore, the introduction of workflow management system solutions, such as Galaxy and Chipster, drives demand for technological advancements in data storage and management. Demand for technologically advanced infrastructure to monitor the flow of data analysis process from data generation to preliminary analysis to higher-level analysis has increased. Moreover, NGS data analysis tools are being constantly upgraded for obtaining effective results and higher utility. For instance, in December 2021, Bionano Genomics launched BioDiscovery's NxClinical Software Version 6.1 for genome analysis. The version enables enhanced visualization and interpretation of NGS data for cancer and genetic disease domains. Such developments are anticipated to drive the industry over the forecast period.

Next-generation Sequencing Data Analysis Market Report Highlights:

  • The services product segment dominated the industry in 2024. NGS has several advantages, in terms of speed and affordability, and many research institutes are unable to adopt it due to a lack of skilled professionals and sufficient computational infrastructure.
  • The tertiary analysis workflow segment captured the major revenue share in 2024 as it accounts for the complex and important step of NGS, which is linked with the interpretation of the results.
  • The in-house mode segment dominated the market in 2024 and is anticipated to remain dominant in the coming years. However, the outsourced mode segment is anticipated to witness the fastest growth rate from 2025 to 2030 owing to time and cost advantages.
  • The short-read sequencing segment held the maximum share in 2024 due to the high adoption of short-read sequencing techniques and their cost-effective nature & ability to work with DNA fragments and the availability of several tools & algorithms.
  • The academic research end-use segment dominated the market in 2024. A reduction in the NGS technology cost has fueled the NGS software platforms usage by several research centers & academic institutions for their research that require data interpretation.
  • North America captured the highest revenue share in 2024 owing to the presence of well-developed information technology companies, favorable reimbursement network, and high government funding and high public & private expenditures in the biotechnology sector.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Product Segment
    • 1.1.2. Workflow Segment
    • 1.1.3. Mode Segment
    • 1.1.4. Read Length Segment
    • 1.1.5. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Primary Research
  • 1.6. Information or Data Analysis:
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations
  • 1.11. Objective

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Demand for efficient algorithms and tools for analysis of large amount of data generated by sequencers
      • 3.2.1.2. Introduction of technological advancements in cloud computing and data integration
      • 3.2.1.3. Increasing penetration of the NGS technology in personalized medicine and precision diagnosis
      • 3.2.1.4. Rising academic research based on NGS protocols
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Challenges in sequence compression and data storage
      • 3.2.2.2. Selection of appropriate algorithms and parallelizing scientific workflows
      • 3.2.2.3. Budget and time constraints
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Product Group Business Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. Next-generation Sequencing Data Analysis Market Product Movement Analysis
  • 4.3. Next-generation Sequencing Data Analysis Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Services
    • 4.4.1. Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. NGS Commercial Software
    • 4.5.1. NGS commercial software market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Platform OS/UI
      • 4.5.2.1. Platform OS/UI market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Analytical Software
      • 4.5.3.1. Analytical software market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.5.3.2. QC/pre-processing tools
        • 4.5.3.2.1. QC/pre-processing tools market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.5.3.3. Alignment tools & software
        • 4.5.3.3.1. Alignment tools & software market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.5.3.3.2. DNA sequencing alignment
          • 4.5.3.3.2.1. DNA sequencing alignment market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.5.3.3.3. RNA sequencing alignment
          • 4.5.3.3.3.1. RNA sequencing alignment market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.5.3.3.4. Protein sequencing alignment
          • 4.5.3.3.4.1. Protein sequencing alignment market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.5.3.4. Others
        • 4.5.3.4.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Workflow Group Business Analysis

  • 5.1. Workflow Segment Dashboard
  • 5.2. Next-generation Sequencing Data Analysis Market Workflow Movement Analysis
  • 5.3. Next-generation Sequencing Data Analysis Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
  • 5.4. Primary
    • 5.4.1. Primary market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Secondary
    • 5.5.1. Secondary market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.2. Read Mapping
      • 5.5.2.1. Read mapping market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Variant Alignment & Variant Calling
      • 5.5.3.1. Variant alignment & variant calling market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Tertiary
    • 5.6.1. Tertiary market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.2. Variant Annotation
      • 5.6.2.1. Variant annotation market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. Application Specific
      • 5.6.3.1. Application specific market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.3.2. Targeted Sequencing/Gene Panel
        • 5.6.3.2.1. Targeted sequencing/gene panel market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.3.3. Exome
        • 5.6.3.3.1. Exome market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.3.4. RNA Sequencing
        • 5.6.3.4.1. RNA sequencing market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.3.5. Whole Genome
        • 5.6.3.5.1. Whole genome market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.3.6. Chip Sequencing
        • 5.6.3.6.1. Chip sequencing market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.3.7. Others
        • 5.6.3.7.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Mode Group Business Analysis

  • 6.1. Mode Segment Dashboard
  • 6.2. Next-generation Sequencing Data Analysis Market Mode Movement Analysis
  • 6.3. Next-generation Sequencing Data Analysis Market Size & Trend Analysis, by Mode, 2018 to 2030 (USD Million)
  • 6.4. In-house Data Analysis
    • 6.4.1. In-house data analysis market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Outsourced Data Analysis
    • 6.5.1. Outsourced data analysis market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Read Length Group Business Analysis

  • 7.1. Read Length Segment Dashboard
  • 7.2. Next-generation Sequencing Data Analysis Market Read Length Movement Analysis
  • 7.3. Next-generation Sequencing Data Analysis Market Size & Trend Analysis, by Read Length, 2018 to 2030 (USD Million)
  • 7.4. Short Read Sequencing
    • 7.4.1. Short read sequencing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5. Long Read Sequencing
    • 7.5.1. Long read sequencing market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6. Very Long Read Sequencing
    • 7.6.1. Very long read sequencing market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. End Use Business Analysis

  • 8.1. End Use Segment Dashboard
  • 8.2. Next-generation Sequencing Data Analysis Market End Use Movement Analysis
  • 8.3. Next-generation Sequencing Data Analysis Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 8.4. Academic Research
    • 8.4.1. Academic research market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5. Clinical Research
    • 8.5.1. Clinical research market estimates and forecasts, 2018-2030 (USD Million)
  • 8.6. Hospitals & Clinics
    • 8.6.1. Hospitals & clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.7. Pharma & Biotech Entities
    • 8.7.1. Pharma& biotech entities market estimates and forecasts, 2018-2030 (USD Million)
  • 8.8. Other
    • 8.8.1. Other market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Regional Business Analysis by Product, Workflow, Mode, Read Length, End Use

  • 9.1. Regional Dashboard
  • 9.2. Market Size & Forecast and Trend Analysis, 2024 & 2030
  • 9.3. North America
    • 9.3.1. North America Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.3.2. U.S.
      • 9.3.2.1. Key Country Dynamics
      • 9.3.2.2. Competitive Scenario
      • 9.3.2.3. U.S. Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.3.3. Canada
      • 9.3.3.1. Key Country Dynamics
      • 9.3.3.2. Competitive Scenario
      • 9.3.3.3. Canada Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.3.4. Mexico
      • 9.3.4.1. Key Country Dynamics
      • 9.3.4.2. Competitive Scenario
      • 9.3.4.3. Mexico Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
  • 9.4. Europe
    • 9.4.1. Europe Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.4.2. UK
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Competitive Scenario
      • 9.4.2.3. UK Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.4.3. Germany
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Competitive Scenario
      • 9.4.3.3. Germany Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.4.4. France
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Competitive Scenario
      • 9.4.4.3. France Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.4.5. Italy
      • 9.4.5.1. Key Country Dynamics
      • 9.4.5.2. Competitive Scenario
      • 9.4.5.3. Italy Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.4.6. Spain
      • 9.4.6.1. Key Country Dynamics
      • 9.4.6.2. Competitive Scenario
      • 9.4.6.3. Spain Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.4.7. Denmark
      • 9.4.7.1. Key Country Dynamics
      • 9.4.7.2. Competitive Scenario
      • 9.4.7.3. Denmark Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.4.8. Sweden
      • 9.4.8.1. Key Country Dynamics
      • 9.4.8.2. Competitive Scenario
      • 9.4.8.3. Sweden Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.4.9. Norway
      • 9.4.9.1. Key Country Dynamics
      • 9.4.9.2. Competitive Scenario
      • 9.4.9.3. Norway Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Asia Pacific Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.5.2. Japan
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Competitive Scenario
      • 9.5.2.3. Japan Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.5.3. China
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Competitive Scenario
      • 9.5.3.3. China Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.5.4. India
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Competitive Scenario
      • 9.5.4.3. India Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.5.5. Australia
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Competitive Scenario
      • 9.5.5.3. Australia Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.5.6. Thailand
      • 9.5.6.1. Key Country Dynamics
      • 9.5.6.2. Competitive Scenario
      • 9.5.6.3. Thailand Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.5.7. South Korea
      • 9.5.7.1. Key Country Dynamics
      • 9.5.7.2. Competitive Scenario
      • 9.5.7.3. South Korea Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
  • 9.6. Latin America
    • 9.6.1. Latin America Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.6.2. Brazil
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Competitive Scenario
      • 9.6.2.3. Brazil Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.6.3. Argentina
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Competitive Scenario
      • 9.6.3.3. Argentina Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
  • 9.7. MEA
    • 9.7.1. MEA Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.7.2. South Africa
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Competitive Scenario
      • 9.7.2.3. South Africa Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.7.3. Saudi Arabia
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Competitive Scenario
      • 9.7.3.3. Saudi Arabia Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.7.4. UAE
      • 9.7.4.1. Key Country Dynamics
      • 9.7.4.2. Competitive Scenario
      • 9.7.4.3. UAE Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)
    • 9.7.5. Kuwait
      • 9.7.5.1. Key Country Dynamics
      • 9.7.5.2. Competitive Scenario
      • 9.7.5.3. Kuwait Next-generation Sequencing Data Analysis Market, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Company Categorization
  • 10.2. Strategy Mapping
  • 10.3. Company Market Position Analysis, 2024
  • 10.4. Company Profiles/Listing
    • 10.4.1. Thermo Fisher Scientific, Inc.
      • 10.4.1.1. Overview
      • 10.4.1.2. Financial Performance
      • 10.4.1.3. Product Benchmarking
      • 10.4.1.4. Strategic Initiatives
    • 10.4.2. Bio-Rad Laboratories, Inc.
      • 10.4.2.1. Overview
      • 10.4.2.2. Financial Performance
      • 10.4.2.3. Product Benchmarking
      • 10.4.2.4. Strategic Initiatives
    • 10.4.3. Pacific Biosciences of California, Inc.
      • 10.4.3.1. Overview
      • 10.4.3.2. Financial Performance
      • 10.4.3.3. Product Benchmarking
      • 10.4.3.4. Strategic Initiatives
    • 10.4.4. QIAGEN
      • 10.4.4.1. Overview
      • 10.4.4.2. Financial Performance
      • 10.4.4.3. Product Benchmarking
      • 10.4.4.4. Strategic Initiatives
    • 10.4.5. Eurofins Scientific
      • 10.4.5.1. Overview
      • 10.4.5.2. Financial Performance
      • 10.4.5.3. Product Benchmarking
      • 10.4.5.4. Strategic Initiatives
    • 10.4.6. Partek Incorporated
      • 10.4.6.1. Overview
      • 10.4.6.2. Financial Performance
      • 10.4.6.3. Product Benchmarking
      • 10.4.6.4. Strategic Initiatives
    • 10.4.7. F. Hoffmann-La Roche Ltd.
      • 10.4.7.1. Overview
      • 10.4.7.2. Financial Performance
      • 10.4.7.3. Product Benchmarking
      • 10.4.7.4. Strategic Initiatives
    • 10.4.8. Illumina, Inc.
      • 10.4.8.1. Overview
      • 10.4.8.2. Financial Performance
      • 10.4.8.3. Product Benchmarking
      • 10.4.8.4. Strategic Initiatives
    • 10.4.9. Agilent Technologies Inc.
      • 10.4.9.1. Overview
      • 10.4.9.2. Financial Performance
      • 10.4.9.3. Product Benchmarking
      • 10.4.9.4. Strategic Initiatives
    • 10.4.10. DNASTAR, Inc
      • 10.4.10.1. Overview
      • 10.4.10.2. Financial Performance
      • 10.4.10.3. Product Benchmarking
      • 10.4.10.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦